查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830982

摄护腺癌治疗市场

Prostate Cancer Therapeutics Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

摄护腺癌治疗市场预计将从 2024 年的 173.7 亿美元增加到 2031 年的 308.3 亿美元，2025 年至 2031 年的复合年增长率预计为 8.5%。

市场洞察与分析师观点：前列腺癌治疗市场正在蓬勃发展，这得益于旨在开发新药化合物的研发力度加大、前列腺癌发病率上升以及政府对前列腺癌诊断的支持力度加大。此外，市场参与者提供的先进产品也推动了市场扩张。 2023年1月，BDR Pharmaceuticals在印度推出了阿帕鲁胺的仿製药，商品名为APATIDE，用于治疗非转移性去势抵抗性前列腺癌和转移性去势敏感性前列腺癌。

成长动力与挑战：摄护腺癌是男性最常见的健康问题之一，尤其针对50岁以上男性。肥胖或有家族病史的男性更易罹患摄护腺癌。摄护腺癌通常发展缓慢，没有明显症状，因此早期发现颇具挑战性。大多数前列腺癌起源于前列腺外周区域，通常只有当癌细胞生长到足以压迫尿道，或出现转移性骨痛时才会出现症状。 50岁以上男性若有下泌尿道症状、勃起功能障碍或血尿，应考虑摄护腺癌的可能性。在全球范围内，摄护腺癌是男性癌症相关死亡的第五大原因，也是第二常见癌症。儘管自2000年以来前列腺癌发生率有所下降，但自2010年以来，晚期前列腺癌病例一直在上升。发病率和死亡率差异很大，已开发国家普遍报告发病率较高，但死亡率较低。在美国，摄护腺癌的风险几乎是全球平均的四倍。根据诺华公司统计，2020年全球报告约有140万例前列腺癌新病例，约37.5万例死亡病例。全球前列腺癌发生率的上升和较低的检出率是推动前列腺癌治疗市场成长的关键因素。

策略洞察报告细分和范围：前列腺癌治疗市场按治疗类型、最终用户和地理分类。依治疗类型，包括荷尔蒙疗法、化疗、免疫疗法、标靶疗法等。按最终用户，分为医院、专科诊所和其他。依地域划分，市场细分为北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳洲和亚太其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非和中东和非洲其他地区）以及其他中美洲（巴西、阿根廷和南美洲和其他地区）。

分段分析：前列腺癌治疗市场依治疗类型细分为荷尔蒙治疗、化疗、免疫治疗、标靶治疗等。 2022 年，荷尔蒙治疗领域占据了化疗之后最大的市场份额，预计在 2022 年至 2030 年期间实现最高复合年增长率。化疗仍然是前列腺癌的重要治疗方法，因为它涉及靶向和摧毁新旧癌细胞的药物。化疗可以缓解转移性摄护腺癌的症状，缩小肿瘤，提高生活品质。多西他赛（Taxotere）是荷尔蒙治疗抗药性患者的标准化疗方案，而卡巴他赛（Jevtana）也已被 FDA 批准用于治疗去势抵抗性前列腺癌，特别是对于在多西他赛治疗期间癌症进展的患者。

区域分析：前列腺癌治疗市场按地区进行分析，包括北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美是全球前列腺癌治疗市场成长的主要贡献者，而亚太地区预计在 2022 年至 2030 年期间的复合年增长率最高。美国前列腺癌治疗市场的成长主要受前列腺癌发病率上升、新产品推出和政府措施的推动。例如，2023 年 6 月，阿斯特捷利康和默沙东的 Lynparza (olaparib) 在美国获准用于治疗疑似有害 BRCA 突变 (BRCAm) 转移性去势抵抗性摄护腺癌 (mCRPC) 成年患者。此外，2023 年 11 月，FDA 批准了由安斯泰来製药美国公司生产的恩杂鲁胺，用于治疗具有高转移风险的非转移性去势敏感性前列腺癌 (nmCSPC)。

前列腺癌治疗市场报告范围行业发展和未来机会：前列腺癌治疗市场主要参与者的关键倡议包括：

2022年3月，美国FDA核准诺华公司的Pluvicto（镥Lu 177 vipivotide tetraxetan）用于治疗晚期前列腺癌（前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌（PSMA阳性mCRPC））成年患者。 2023年4月，FDA授予Lantheus Holdings Inc和POINT Biopharma Global Inc 177Lu-PNT2002的快速通道资格，旨在治疗转移性去势抵抗性前列腺癌（mCRPC）。 PNT2002是一种创新的PSMA靶向177Lu放射性药物疗法，它将PSMA靶向配体PSMA-I&T与β发射放射性同位素（无载体添加177Lu）相结合，用于转移性去势抵抗性前列腺癌（mCRPC）治疗。竞争格局和主要公司：前列腺癌治疗市场的知名企业包括安斯泰来製药公司、强生服务公司、礼来公司、拜耳公司、赛诺菲、默克公司、阿斯特捷利康、诺华公司、艾伯维和百时美施贵宝。这些公司专注于推出新产品并进行地理扩张，以满足不断增长的全球需求并增强其特色产品组合。他们的国际影响力使他们能够满足广泛的客户群，从而促进市场成长。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：前列腺癌治疗市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：前列腺癌治疗市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：前列腺癌治疗市场－全球市场分析

  • 前列腺癌治疗 - 全球市场概览
  • 前列腺癌治疗－全球市场及2030年预测

第七章：前列腺癌治疗市场 - 收入分析 - 按疗法，2020-2030 年

  • 概述
  • 荷尔蒙疗法
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 其他的

第 8 章：前列腺癌治疗市场 - 收入分析 - 按配销通路，2020-2030 年

  • 概述
  • 医院
  • 专科诊所
  • 其他的

第九章：前列腺癌治疗市场-收入分析，2020-2030-地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 12 章：前列腺癌治疗市场 - 主要公司简介

  • Johnson and Johnson Services, Inc.
  • Bayer AG
  • AstraZeneca
  • Astellas Pharma Inc
  • Eli, Lilly, and Company
  • Sanofi
  • AbbVie Inc.
  • Merck KGaA
  • Novartis AG
  • Bristol Myers Squibb

第 13 章：附录

简介目录
Product Code: TIPRE00003423

The prostate cancer therapeutics market is projected to increase from US$ 17.37 billion in 2024 to US$ 30.83 billion by 2031, with an expected CAGR of 8.5% from 2025 to 2031.

Market Insights and Analyst Perspective:The prostate cancer therapeutics market is growing due to heightened R&D efforts aimed at developing new drug compounds, a rising incidence of prostate cancer cases, and increased government support for prostate cancer diagnostics. Furthermore, the availability of advanced products from market players is propelling market expansion. In January 2023, BDR Pharmaceutical introduced a generic version of Apalutamide, marketed as APATIDE, in India, which is used to treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Growth Drivers and Challenges:Prostate cancer ranks among the most prevalent health issues for men, particularly those aged 50 and older. It is more common in men who are obese or have a family history of the disease. Often, prostate cancer develops silently without noticeable symptoms, making early detection challenging. Most prostate cancers begin in the peripheral zone of the prostate gland, and symptoms typically emerge only when the cancer grows large enough to press on the urethra, or when bone pain from metastasis occurs. Men aged 50 and above experiencing lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Globally, prostate cancer is the fifth leading cause of cancer-related deaths among men and the second most frequently diagnosed cancer. Although there has been a decline in prostate cancer incidence since 2000, cases of late-stage prostate cancer have been on the rise since 2010. Incidence and mortality rates vary significantly, with developed countries generally reporting higher incidence but lower mortality rates. In the US, the risk of prostate cancer is nearly four times higher than the global average. According to Novartis AG, approximately 1.4 million new prostate cancer cases and around 375,000 deaths were reported worldwide in 2020. The increasing global incidence of prostate cancer and low detection rates are key factors driving the growth of the prostate cancer therapeutics market.

Strategic Insights

Report Segmentation and Scope:The prostate cancer therapeutics market is categorized by therapy type, end user, and geography. By therapy type, it includes hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. By end user, it is divided into hospitals, specialty clinics, and others. Geographically, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The prostate cancer therapeutics market is segmented by therapy type into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the hormone therapy segment held the largest market share after chemotherapy, and it is expected to achieve the highest CAGR from 2022 to 2030. Chemotherapy remains a crucial treatment for prostate cancer, as it involves drugs that target and destroy both new and existing cancer cells. Chemotherapy can alleviate symptoms of metastatic prostate cancer, reduce tumor size, and enhance quality of life. Docetaxel (Taxotere) is the standard treatment for chemotherapy in patients resistant to hormone therapy, while cabazitaxel (Jevtana) has also been approved by the FDA for treating castration-resistant prostate cancer, particularly in patients whose cancer has progressed during docetaxel treatment.

Regional Analysis:The prostate cancer therapeutics market is analyzed by region, including North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the leading contributor to the global growth of the prostate cancer therapeutics market, while Asia Pacific is anticipated to exhibit the highest CAGR from 2022 to 2030. The growth of the prostate cancer therapeutics market in the US is primarily driven by the rising incidence of prostate cancer, new product launches, and government initiatives. For instance, in June 2023, AstraZeneca and MSD's Lynparza (olaparib) was approved in the US for treating adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Additionally, in November 2023, the FDA approved enzalutamide, manufactured by Astellas Pharma US, Inc., for treating non-metastatic castration-sensitive prostate cancer (nmCSPC) with a high risk of metastasis.

Prostate Cancer Therapeutics Market Report ScopeIndustry Developments and Future Opportunities:Key initiatives by major players in the prostate cancer therapeutics market include:

In March 2022, the US FDA approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients with advanced prostate cancer known as prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).

In April 2023, the FDA granted fast track designation to Lantheus Holdings Inc and POINT Biopharma Global Inc for 177Lu-PNT2002, aimed at treating metastatic castration-resistant prostate cancer (mCRPC). PNT2002 is an innovative PSMA-targeted 177Lu-based radiopharmaceutical therapy that combines a PSMA-targeted ligand, PSMA-I&T, with a beta-emitting radioisotope, no-carrier-added 177Lu for mCRPC treatment.Competitive Landscape and Key Companies:Prominent players in the prostate cancer therapeutics market include Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb. These companies focus on launching new products and expanding geographically to meet the growing global demand and enhance their specialty product portfolios. Their international presence enables them to cater to a broad customer base, thereby facilitating market growth.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Prostate Cancer Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Prostate Cancer Therapeutics Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Prostate Cancer Therapeutics Market - Global Market Analysis

  • 6.1 Prostate Cancer Therapeutics - Global Market Overview
  • 6.2 Prostate Cancer Therapeutics - Global Market and Forecast to 2030

7. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Therapy, 2020-2030

  • 7.1 Overview
  • 7.2 Hormonal Therapy
  • 7.3 Chemotherapy
  • 7.4 Targeted Therapy
  • 7.5 Immunotherapy
  • 7.6 Others

8. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 8.1 Overview
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Others

9. Prostate Cancer Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Prostate Cancer Therapeutics Market Overview
    • 9.1.2 North America Prostate Cancer Therapeutics Market Revenue and Forecasts to 2030
    • 9.1.3 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Therapy
    • 9.1.4 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 9.1.5 North America Prostate Cancer Therapeutics Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Prostate Cancer Therapeutics Market
        • 9.1.5.1.1 United States Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.1.2 United States Prostate Cancer Therapeutics Market, by Distribution Channel
      • 9.1.5.2 Canada Prostate Cancer Therapeutics Market
        • 9.1.5.2.1 Canada Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.2.2 Canada Prostate Cancer Therapeutics Market, by Distribution Channel
      • 9.1.5.3 Mexico Prostate Cancer Therapeutics Market
        • 9.1.5.3.1 Mexico Prostate Cancer Therapeutics Market, by Therapy
        • 9.1.5.3.2 Mexico Prostate Cancer Therapeutics Market, by Distribution Channel
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Prostate Cancer Therapeutics Market - Key Company Profiles

  • 12.1 Johnson and Johnson Services, Inc.
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Bayer AG
  • 12.3 AstraZeneca
  • 12.4 Astellas Pharma Inc
  • 12.5 Eli, Lilly, and Company
  • 12.6 Sanofi
  • 12.7 AbbVie Inc.
  • 12.8 Merck KGaA
  • 12.9 Novartis AG
  • 12.10 Bristol Myers Squibb

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud